Loading patent…
AssigneesEmory University, Merck Sharp & Dohme Corp.
InventorsJameson R. Bothe, Andrew Patrick Jude Brunskill, Mark Lockwood, Justin Allen Newman, Manohar T. Saindane
Estimating the term…
Novel crystalline forms of molnupiravir, including crystalline Forms I and II, which are crystalline forms of uridine 4-oxime 5′-(2-methylpropanoate), may be useful as antiviral agents, specifically as antiviral treatments for infections caused by Eastern Equine Encephalitis Virus (EEEV), Western Equine Encephalitis Virus (WEEV), and Venezuelan Equine Encephalitis Virus (VEEV), Chikungunya fever virus (CHIK), Ebola virus, influenza virus, respiratory syncytial virus (RSV), Zika virus, and coronaviruses, such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and, most recently, SARS-CoV-2 (also known as 2019-nCoV).
Crystalline form of {(2R,3S,4R,5R)-3,4-dihydroxy-5-[(4Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1 (2H)-yl]oxolan-2-yl}methyl 2-methylpropanoate, wherein said crystalline form is characterized by an X-ray powder diffraction pattern containing at least four ° 2θ values measured using CuKα radiation chosen from:
Crystalline form of {(2R,3S,4R,5R)-3,4-dihydroxy-5-[(4Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1 (2H)-yl]oxolan-2-yl}methyl 2-methylpropanoate, wherein said crystalline form is characterized by an X-ray powder diffraction pattern containing
Dependencies are inferred from the claim text.